Liver King TRT: What Clinicians Should Tell Patients

Who Is Liver King and Why Are Patients Asking About Him?

Brian Johnson, better known by his social media persona "Liver King," built a following exceeding 10 million across platforms by promoting the "ancestral lifestyle." His core marketing message was that eating raw animal organs, performing primal workouts, and following nine "ancestral tenets" could produce his level of muscularity without pharmaceutical assistance.

Patients, predominantly men aged 18 to 45, encountered his content and presented to clinicians asking whether TRT or "ancestral eating" could explain his physique. His case is now a teaching moment.

The December 2022 Admission

In November 2022, fitness commentator Derek of More Plates More Dates published a leaked email attributed to Johnson. The email detailed a monthly PED budget of approximately $11,000, covering compounds including testosterone enanthate, insulin-like growth factor-1 (IGF-1), HGH, and several other anabolic agents. Johnson initially denied authenticity.

On December 2, 2022, Johnson posted a 45-minute YouTube video titled "I've Been Lying To You." He stated directly: "I was wrong. I misled you. I'm on TRT, and I've been on more than TRT." He acknowledged using multiple anabolic compounds while publicly attributing his physique solely to diet and ancestral practices.

Why This Matters Clinically

The admission matters for one reason that has nothing to do with celebrity gossip. Patients who followed Johnson's content for two-plus years received systematically false information about what was physiologically achievable without drugs. That misinformation shapes unrealistic expectations, drives unsupervised AAS acquisition, and creates risk.

What Compounds Did Liver King Actually Use?

The leaked email and Johnson's own admission describe a regimen consistent with a competitive bodybuilder's off-season PED stack, not a therapeutic TRT protocol.

Anabolic-Androgenic Steroids

The email references testosterone enanthate at doses not disclosed per week, though the overall monthly spend and compound list suggest supraphysiologic dosing far above the standard therapeutic range of 75-100 mg testosterone weekly used in hypogonadism management per Endocrine Society guidelines [1].

Testosterone enanthate at supraphysiologic doses suppresses the hypothalamic-pituitary-gonadal (HPG) axis, raises hematocrit, increases left ventricular mass, and causes dose-dependent dyslipidemia. A 2013 systematic review in JAMA Internal Medicine (N=51 trials) found that exogenous testosterone significantly reduced HDL cholesterol across all dose ranges studied [2].

Human Growth Hormone

The email lists HGH alongside IGF-1. HGH at supraphysiologic doses promotes lipolysis and lean mass accretion but carries well-characterized risks: acromegaloid changes, carpal tunnel syndrome, insulin resistance, and potential cardiomegaly. The FDA has not approved HGH for bodybuilding or physique enhancement [3].

Insulin and Other Agents

The leaked document also references insulin use, one of the highest-risk compounds used in bodybuilding. Exogenous insulin in non-diabetic individuals without continuous glucose monitoring carries a real risk of fatal hypoglycemia. This is not a theoretical concern. Multiple case reports in the literature document deaths among bodybuilders using insulin periworkout [4].

Clinicians should recognize that the compound list described is not a supervised TRT protocol. It describes polypharmacy with multiple Schedule III controlled substances and unapproved HGH use.

The Physiology of His Physique: What Patients Need to Understand

Patients often arrive with a photograph of Johnson and ask whether diet, sleep optimization, or TRT could produce his muscular development. A direct physiological answer is more useful than a vague disclaimer.

Skeletal Muscle Hypertrophy Requires Androgen Signal

Testosterone and its synthetic analogs bind the androgen receptor in skeletal muscle and upregulate IGF-1 signaling locally, driving satellite cell proliferation and myofibrillar protein synthesis. The dose-response relationship between testosterone and fat-free mass is well established. A landmark 1996 NEJM trial by Bhasin et al. (N=43) demonstrated that 600 mg testosterone enanthate per week for 10 weeks produced 6.1 kg of fat-free mass gain without exercise, compared to 1.9 kg in placebo-exercising controls [5]. Diet alone cannot replicate this signal.

What Therapeutic TRT Actually Produces

Standard TRT, at 75-100 mg testosterone enanthate or cypionate weekly, restores serum testosterone to the mid-normal physiologic range (400-700 ng/dL). In symptomatic hypogonadal men, this modestly improves lean mass, bone density, and quality of life. The 2016 Testosterone Trials (TTrials, N=790) showed a mean fat-free mass increase of 2.7 kg and a decrease in fat mass of 1.6 kg over one year at physiologic replacement doses [6].

That is a meaningful clinical outcome for a hypogonadal man. It is not the physique displayed by Johnson. His admitted stack operated at supraphysiologic levels across multiple anabolic axes simultaneously.

Raw Organ Consumption: Legitimate Micronutrient Source, Not Anabolic Driver

Johnson's "ancestral" diet included raw liver, raw testicles, and other organ meats. Liver is genuinely nutrient-dense: it provides retinol (vitamin A), heme iron, folate, riboflavin, and cobalamin in high concentrations. Raw testicles contain trace androgens, but enteral absorption of intact steroid hormones from food is negligible compared with pharmaceutical delivery. There is no peer-reviewed evidence that eating animal testes meaningfully raises serum testosterone in humans. Clinicians can simply state this fact.

Cardiovascular and Endocrine Risks of the Stack He Described

Cardiovascular Risk

Supraphysiologic AAS use is associated with adverse cardiovascular remodeling. A 2017 study published in Circulation (N=140) found that former AAS users had significantly impaired left ventricular systolic function compared to both current users and non-users, with mean ejection fraction 52% vs. 63% in non-users (P<0.001) [7]. The authors noted that impairment persisted years after cessation.

A 2023 meta-analysis in the European Heart Journal (N=35 studies, 5,766 AAS users) found a pooled odds ratio of 2.74 for major adverse cardiovascular events among AAS users compared to non-users [8].

HPG Axis Suppression and Recovery

Exogenous testosterone suppresses LH and FSH via negative feedback. After cessation of a prolonged supraphysiologic cycle, HPG axis recovery may take 6-24 months, and in some cases does not fully recover. Clinicians managing men who come off unsupervised AAS cycles should measure LH, FSH, total testosterone, and estradiol at baseline and at 3, 6, and 12 months post-cycle. Post-cycle therapy protocols (clomiphene 25-50 mg daily or tamoxifen 20 mg daily) are used off-label to accelerate axis recovery, though high-quality randomized trial data on these protocols remain limited [9].

Hepatotoxicity

17-alpha-alkylated oral anabolic steroids carry well-documented hepatotoxic risk. Injectable testosterone esters are less hepatotoxic but large-scale unsupervised AAS use still appears in drug-induced liver injury registries. The FDA MedWatch database includes cases of cholestatic jaundice associated with AAS [3].

Psychological Effects

AAS use at supraphysiologic doses is associated with increased aggression, mood instability, and dependence. A 2000 review in Archives of General Psychiatry noted that approximately 30% of long-term AAS users develop dependence criteria [10]. Clinicians should screen patients disclosing unsupervised AAS use for mood disorder and substance use disorder comorbidities.

Evidence-Based Talking Points for the Clinical Encounter

When a patient presents asking about Liver King's regimen, the following framework gives clinicians a structured, non-judgmental response.

Acknowledge, Then Correct the Information Gap

Start by validating the patient's curiosity. "You saw someone claiming a natural physique, and that made you wonder what's actually possible. That's a reasonable question." Then provide the factual correction: Johnson admitted using testosterone, HGH, and multiple other compounds at doses well above any therapeutic protocol.

Avoid moralizing. Patients who feel judged disengage. The goal is accurate calibration of expectations.

Address the "Just TRT" Framing Patients Often Use

Some patients use Johnson's story to ask whether they could get "just a little TRT" to look the way he does. The clinical answer is direct: therapeutic TRT restores normal physiology in men with documented hypogonadism. The TTrials showed 2.7 kg lean mass gain over 12 months at physiologic doses [6]. Johnson's physique required supraphysiologic polypharmacy, not therapeutic replacement.

If a patient has genuine symptoms of hypogonadism (fatigue, low libido, reduced morning erections, depressed mood), they should be evaluated with a morning total testosterone level. The Endocrine Society defines biochemical hypogonadism as two fasting morning total testosterone measurements below 300 ng/dL with concomitant symptoms [1]. Treatment is appropriate for confirmed cases. Treatment to achieve a physique seen on social media is a different clinical category.

Screen for Unsupervised AAS Use

Some patients who ask about Liver King are already using black-market AAS. Non-judgmental screening questions include:

• "Have you used any testosterone or growth hormone outside of a prescription?"
• "Have you purchased any compounds online or from a gym contact?"

If the answer is yes, order a metabolic panel, lipid panel, CBC, LFTs, LH, FSH, total testosterone, estradiol, and PSA (if age-appropriate). These patients need harm reduction, not a lecture.

Cite the Cardiovascular Data Directly

Patients who are considering AAS use often respond to specific numbers. The European Heart Journal meta-analysis showing an OR of 2.74 for major adverse cardiovascular events is a concrete, nameable data point [8]. Paired with the Circulation finding of mean ejection fraction 52% in former users vs. 63% in non-users [7], these numbers give patients something real to weigh against aesthetic goals.

What the Legal Context Adds

In early 2023, a class-action lawsuit was filed against Johnson and Ancestral Supplements, alleging that his false claims about his physique being "natural" constituted deceptive marketing for his supplement products. As of this writing, the litigation has not fully resolved. The legal outcome does not change the clinical picture, but it contextualizes the commercial incentive behind his public denials.

The FTC has increasing interest in influencer supplement marketing claims. Clinicians advising patients on this case can note that the regulatory and legal systems are now responding to what the physiology already made obvious.

What Legitimate TRT Looks Like by Contrast

Patients deserve a clear picture of what evidence-based testosterone therapy actually involves, not as a defense of a company's product, but as a clinical baseline.

The Endocrine Society 2018 guideline recommends TRT for men with confirmed hypogonadism (two morning total testosterone <300 ng/dL plus symptoms) [1]. First-line options include:

• Testosterone cypionate or enanthate 75-100 mg IM or subcutaneous weekly (or 150-200 mg every two weeks)
• Testosterone gel 1.62% (AndroGel), 20.25-81 mg daily to skin
• Testosterone pellets (Testopel) 150-450 mg subcutaneously every 3-6 months

Monitoring includes serum testosterone (target mid-normal range, 400-700 ng/dL), hematocrit at 3 and 6 months, PSA annually in men over 40, and lipid panel at 12 months. This is supervised, dose-appropriate care with a defined physiologic target. It is the opposite of what the leaked email described.

"The goal of testosterone therapy in hypogonadal men is to restore serum testosterone to the mid-normal range for healthy young men," states the Endocrine Society 2018 Clinical Practice Guideline, "not to exceed the upper limit of normal." [1]

The Broader Pattern: Why Celebrity PED Disclosures Keep Recurring

Johnson is not an isolated case. The pattern of a public figure denying drug use, building a brand around that denial, and then admitting use after external exposure is now well-documented in the fitness space. Clinicians see the downstream effect: patients arrive with distorted baselines for what is achievable naturally, and some arrive having already acted on those distorted baselines.

A 2019 study in Drug and Alcohol Dependence (N=231 AAS-using men) found that 56% reported that exposure to social media fitness content was a factor in their initial decision to use AAS [11]. This is not a small or anecdotal influence. Social media physique culture is a legitimate upstream driver of unsupervised AAS use in your clinic population.

The American Urological Association and the Endocrine Society have both noted rising rates of exogenous androgen exposure in young men presenting with secondary hypogonadism. Clinicians seeing young men with low LH, low FSH, and suppressed testosterone should always ask about unsupervised androgen use before attributing findings to primary hypogonadal disease.

A Note on Ancestral Supplements and Organ Meat Marketing

Johnson's company, Ancestral Supplements, sells desiccated organ capsules. These products contain real nutrients. Grass-fed beef liver capsules provide retinol, heme iron, and B vitamins. The clinical concern is not that these products are dangerous. The concern is the marketing claim that they produce pharmacological effects on testosterone or muscle mass comparable to anabolic compounds.

Desiccated bovine testicle capsules, for example, contain minimal intact androgens after processing. No clinical trial data support the claim that they meaningfully raise serum testosterone. Patients asking whether they should take organ supplements to "naturally boost testosterone" should be told: these products provide micronutrients and are not a substitute for evaluation of actual hypogonadism, nor do they produce anabolic effects comparable to pharmaceutical testosterone.